There has been another round of promoter selling. Promoter has sold around 2% in November 2023.
The previous promoter sale happened in 2017.
Disclosure: Invested and may be biased. Not a buy or sell recommendation.
Posts in category Value Pickr
Deepak Fertilizers and Petrochemicals (09-11-2023)
Ammonia price is increasing which will generate good delta for newly commissioned Ammonia CAPEX…
The HS Portfolio (09-11-2023)
Dont I know it. Was a large chunk too of PF.
But in Investing it has to be learn the lesson, move on and carry on.
The HS Portfolio (09-11-2023)
Dont I know it. Was a large chunk too of PF.
But in Investing it has to be learn the lesson, move on and carry on.
MCX and Financial Technologies (09-11-2023)
I think they said no cost in the first year, as it is covered under project implementation cost which will hit capex. After that, annual running costs would be significantly lower (comparatively) but was to be disclosed later. Hopefully in the next earnings call.
MCX and Financial Technologies (09-11-2023)
I think they said no cost in the first year, as it is covered under project implementation cost which will hit capex. After that, annual running costs would be significantly lower (comparatively) but was to be disclosed later. Hopefully in the next earnings call.
Man Infraconstruction Limited – From Ports & Civil Infra to Real Estate Development (09-11-2023)
Quarterly sales down by more than 50%. Management did not comment on Q-to-Q basis. But looks postive for long term. The price may consolidate at CMP until the next quarter results.
Disclaimer:i am invested in this co.
SKM Egg Products – thinking out of the shell (09-11-2023)
There is nothing to track day to day… Company looks postive for long term and waitng for the Q2 result. Next big growth should come from dmestic market.
Disclaimer:i am invested in this co.
Alembic Pharma (Oral Solids ==> Injectables, Onco, Derma, Opthalmic) (08-11-2023)
Alembic Pharma reported muted nos, with sales growing by 8% and EPS largely being flat. They have started launching injectable, onco and derma products in US. Their non-US market is doing very well. Concall notes below.
FY24Q2
- 12MW solar plant commissioned in October 2023, ROI of 18-20%
- Animal health business has now scaled to 98 cr. quarterly run rate (32% growth). Business has grown at 18% CAGR in last 5 years. Established a new division with 350 people. Margins are a tad lower than corporate level profitability
- New facilities contributed 60-70 cr. to quarterly expenses
- Have seen very good pickup in oncology product in US, injectable product has also seen good market share gains without much price erosion
- Out of 20 planned US launched, 10-12 will be OSDs and remaining will be ophthalmic injectable and derma products
- US filing rate has reduced from 20-25 products to 15 now (will reduce R&D spends)
- Will launch 10+ products in US in H2
Disclosure: Invested (position size here, bought shares in last-30 days)